Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice

Jiapeng Wang, Zhaomin Li, Yongzheng He, Feng Pan, Shi Chen, Steven Rhodes, Lihn Nguyen, Jin Yuan, Li Jiang, Xianlin Yang, Ophelia Weeks, Ziyue Liu, Jiehao Zhou, Hongyu Ni, Chen Leng Cai, Mingjiang Xu, Feng Chun Yang

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

ASXL1 is mutated/deleted with high frequencies in multiple forms of myeloid malignancies, and its alterations are associated with poor prognosis. De novo ASXL1 mutations cause Bohring-Opitz syndrome characterized by multiple congenital malformations. We show that Asxl1 deletion in mice led to developmental abnormalities including dwarfism, anophthalmia, and 80%embryonic lethality. Surviving Asxl1-/- mice lived for up to 42 days and developed features of myelodysplastic syndrome (MDS), including dysplastic neutrophils and multiple lineage cytopenia. Asxl1-/- mice had a reduced hematopoietic stem cell (HSC) pool, and Asxl1-/- HSCs exhibited decreased hematopoietic repopulating capacity, with skewed cell differentiation favoring granulocytic lineage. Asxl1+/-mice also developed mild MDS-like disease, which could progress to MDS/myeloproliferative neoplasm, demonstrating a haploinsufficient effect of Asxl1 in the pathogenesis of myeloid malignancies. Asxl1 loss led to an increased apoptosis andmitosis in Lineage-c-Kit+ (Lin-c-Kit+) cells, consistent with humanMDS. Furthermore, Asxl1-/- Lin -c-Kit+ cells exhibited decreased global levels of H3K27me3 and H3K4me3 and altered expression of genes regulating apoptosis (Bcl2, Bcl2l12, Bcl2l13). Collectively, we report a novel ASXL1 murine model that recapitulates human myeloid malignancies, implying that Asxl1 functions as a tumor suppressor to maintain hematopoietic cell homeostasis. Future work is necessary to clarify the contribution of microenvironment to the hematopoietic phenotypes observed in the constitutional Asxl-/- mice.

Original languageEnglish
Pages (from-to)541-553
Number of pages13
JournalBlood
Volume123
Issue number4
DOIs
StatePublished - Jan 23 2014

Fingerprint

Myelodysplastic Syndromes
Apoptosis
Stem cells
Tumors
Neoplasms
Genes
Anophthalmos
Dwarfism
Hematopoietic Stem Cells
Cell Differentiation
Neutrophils
Homeostasis
Phenotype
Gene Expression
Mutation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Wang, J., Li, Z., He, Y., Pan, F., Chen, S., Rhodes, S., ... Yang, F. C. (2014). Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood, 123(4), 541-553. https://doi.org/10.1182/blood-2013-05-500272

Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. / Wang, Jiapeng; Li, Zhaomin; He, Yongzheng; Pan, Feng; Chen, Shi; Rhodes, Steven; Nguyen, Lihn; Yuan, Jin; Jiang, Li; Yang, Xianlin; Weeks, Ophelia; Liu, Ziyue; Zhou, Jiehao; Ni, Hongyu; Cai, Chen Leng; Xu, Mingjiang; Yang, Feng Chun.

In: Blood, Vol. 123, No. 4, 23.01.2014, p. 541-553.

Research output: Contribution to journalArticle

Wang, J, Li, Z, He, Y, Pan, F, Chen, S, Rhodes, S, Nguyen, L, Yuan, J, Jiang, L, Yang, X, Weeks, O, Liu, Z, Zhou, J, Ni, H, Cai, CL, Xu, M & Yang, FC 2014, 'Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice', Blood, vol. 123, no. 4, pp. 541-553. https://doi.org/10.1182/blood-2013-05-500272
Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S et al. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood. 2014 Jan 23;123(4):541-553. https://doi.org/10.1182/blood-2013-05-500272
Wang, Jiapeng ; Li, Zhaomin ; He, Yongzheng ; Pan, Feng ; Chen, Shi ; Rhodes, Steven ; Nguyen, Lihn ; Yuan, Jin ; Jiang, Li ; Yang, Xianlin ; Weeks, Ophelia ; Liu, Ziyue ; Zhou, Jiehao ; Ni, Hongyu ; Cai, Chen Leng ; Xu, Mingjiang ; Yang, Feng Chun. / Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. In: Blood. 2014 ; Vol. 123, No. 4. pp. 541-553.
@article{3206709c180743f389c0fb738ed4e634,
title = "Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice",
abstract = "ASXL1 is mutated/deleted with high frequencies in multiple forms of myeloid malignancies, and its alterations are associated with poor prognosis. De novo ASXL1 mutations cause Bohring-Opitz syndrome characterized by multiple congenital malformations. We show that Asxl1 deletion in mice led to developmental abnormalities including dwarfism, anophthalmia, and 80{\%}embryonic lethality. Surviving Asxl1-/- mice lived for up to 42 days and developed features of myelodysplastic syndrome (MDS), including dysplastic neutrophils and multiple lineage cytopenia. Asxl1-/- mice had a reduced hematopoietic stem cell (HSC) pool, and Asxl1-/- HSCs exhibited decreased hematopoietic repopulating capacity, with skewed cell differentiation favoring granulocytic lineage. Asxl1+/-mice also developed mild MDS-like disease, which could progress to MDS/myeloproliferative neoplasm, demonstrating a haploinsufficient effect of Asxl1 in the pathogenesis of myeloid malignancies. Asxl1 loss led to an increased apoptosis andmitosis in Lineage-c-Kit+ (Lin-c-Kit+) cells, consistent with humanMDS. Furthermore, Asxl1-/- Lin -c-Kit+ cells exhibited decreased global levels of H3K27me3 and H3K4me3 and altered expression of genes regulating apoptosis (Bcl2, Bcl2l12, Bcl2l13). Collectively, we report a novel ASXL1 murine model that recapitulates human myeloid malignancies, implying that Asxl1 functions as a tumor suppressor to maintain hematopoietic cell homeostasis. Future work is necessary to clarify the contribution of microenvironment to the hematopoietic phenotypes observed in the constitutional Asxl-/- mice.",
author = "Jiapeng Wang and Zhaomin Li and Yongzheng He and Feng Pan and Shi Chen and Steven Rhodes and Lihn Nguyen and Jin Yuan and Li Jiang and Xianlin Yang and Ophelia Weeks and Ziyue Liu and Jiehao Zhou and Hongyu Ni and Cai, {Chen Leng} and Mingjiang Xu and Yang, {Feng Chun}",
year = "2014",
month = "1",
day = "23",
doi = "10.1182/blood-2013-05-500272",
language = "English",
volume = "123",
pages = "541--553",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice

AU - Wang, Jiapeng

AU - Li, Zhaomin

AU - He, Yongzheng

AU - Pan, Feng

AU - Chen, Shi

AU - Rhodes, Steven

AU - Nguyen, Lihn

AU - Yuan, Jin

AU - Jiang, Li

AU - Yang, Xianlin

AU - Weeks, Ophelia

AU - Liu, Ziyue

AU - Zhou, Jiehao

AU - Ni, Hongyu

AU - Cai, Chen Leng

AU - Xu, Mingjiang

AU - Yang, Feng Chun

PY - 2014/1/23

Y1 - 2014/1/23

N2 - ASXL1 is mutated/deleted with high frequencies in multiple forms of myeloid malignancies, and its alterations are associated with poor prognosis. De novo ASXL1 mutations cause Bohring-Opitz syndrome characterized by multiple congenital malformations. We show that Asxl1 deletion in mice led to developmental abnormalities including dwarfism, anophthalmia, and 80%embryonic lethality. Surviving Asxl1-/- mice lived for up to 42 days and developed features of myelodysplastic syndrome (MDS), including dysplastic neutrophils and multiple lineage cytopenia. Asxl1-/- mice had a reduced hematopoietic stem cell (HSC) pool, and Asxl1-/- HSCs exhibited decreased hematopoietic repopulating capacity, with skewed cell differentiation favoring granulocytic lineage. Asxl1+/-mice also developed mild MDS-like disease, which could progress to MDS/myeloproliferative neoplasm, demonstrating a haploinsufficient effect of Asxl1 in the pathogenesis of myeloid malignancies. Asxl1 loss led to an increased apoptosis andmitosis in Lineage-c-Kit+ (Lin-c-Kit+) cells, consistent with humanMDS. Furthermore, Asxl1-/- Lin -c-Kit+ cells exhibited decreased global levels of H3K27me3 and H3K4me3 and altered expression of genes regulating apoptosis (Bcl2, Bcl2l12, Bcl2l13). Collectively, we report a novel ASXL1 murine model that recapitulates human myeloid malignancies, implying that Asxl1 functions as a tumor suppressor to maintain hematopoietic cell homeostasis. Future work is necessary to clarify the contribution of microenvironment to the hematopoietic phenotypes observed in the constitutional Asxl-/- mice.

AB - ASXL1 is mutated/deleted with high frequencies in multiple forms of myeloid malignancies, and its alterations are associated with poor prognosis. De novo ASXL1 mutations cause Bohring-Opitz syndrome characterized by multiple congenital malformations. We show that Asxl1 deletion in mice led to developmental abnormalities including dwarfism, anophthalmia, and 80%embryonic lethality. Surviving Asxl1-/- mice lived for up to 42 days and developed features of myelodysplastic syndrome (MDS), including dysplastic neutrophils and multiple lineage cytopenia. Asxl1-/- mice had a reduced hematopoietic stem cell (HSC) pool, and Asxl1-/- HSCs exhibited decreased hematopoietic repopulating capacity, with skewed cell differentiation favoring granulocytic lineage. Asxl1+/-mice also developed mild MDS-like disease, which could progress to MDS/myeloproliferative neoplasm, demonstrating a haploinsufficient effect of Asxl1 in the pathogenesis of myeloid malignancies. Asxl1 loss led to an increased apoptosis andmitosis in Lineage-c-Kit+ (Lin-c-Kit+) cells, consistent with humanMDS. Furthermore, Asxl1-/- Lin -c-Kit+ cells exhibited decreased global levels of H3K27me3 and H3K4me3 and altered expression of genes regulating apoptosis (Bcl2, Bcl2l12, Bcl2l13). Collectively, we report a novel ASXL1 murine model that recapitulates human myeloid malignancies, implying that Asxl1 functions as a tumor suppressor to maintain hematopoietic cell homeostasis. Future work is necessary to clarify the contribution of microenvironment to the hematopoietic phenotypes observed in the constitutional Asxl-/- mice.

UR - http://www.scopus.com/inward/record.url?scp=84897019526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897019526&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-05-500272

DO - 10.1182/blood-2013-05-500272

M3 - Article

C2 - 24255920

AN - SCOPUS:84897019526

VL - 123

SP - 541

EP - 553

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -